Relfovetmab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Portela |
| Other names | ZTS-00084768 |
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| Chemical and physical data | |
| Formula | C6580H10118N1760O2038S46 |
| Molar mass | 147964.37 g·mol−1 |
Relfovetmab, sold under the brand name Portela, is a felinized monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats. Relfovetmab targets nerve growth factor. Nerve growth factor binds to TrkA receptors located on immune cells to elicit the release of additional proinflammatory mediators, including nerve growth factor itself. These inflammatory mediators lead to further peripheral sensitization involved in pain perception. The inhibition of nerve growth factor was demonstrated to provide relief from pain associated with osteoarthritis.
Relfovetmab was authorized for veterinary use in the European Union in October 2025, and in Canada in December 2025.